COMT Inhibitors in the Treatment of Parkinson's Disease

E. V. Encarnacion, R. A. Hauser

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Levodopa continues to be the most efficacious dopaminergic agent in the treatment of parkinsonian motor symptoms. Its long term administration, however, combined with the progressive loss of cells in advanced disease, is associated with the wearing 'off' episodes and dyskinesia. COMT inhibition through Tolcapone and Entacapone may alleviate these motor complications.

Original languageEnglish (US)
Title of host publicationEncyclopedia of Movement Disorders
PublisherElsevier Inc.
Pages246-249
Number of pages4
ISBN (Electronic)9780123741059
ISBN (Print)9780123741011
DOIs
StatePublished - Jan 1 2010

Keywords

  • COMT
  • Dyskinesia
  • Entacapone
  • Fluctuation
  • Levodopa
  • Mechanism
  • Parkinson's disease
  • Stalevo
  • Tolcapone
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'COMT Inhibitors in the Treatment of Parkinson's Disease'. Together they form a unique fingerprint.

  • Cite this

    Encarnacion, E. V., & Hauser, R. A. (2010). COMT Inhibitors in the Treatment of Parkinson's Disease. In Encyclopedia of Movement Disorders (pp. 246-249). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-374105-9.00315-4